跳至主要内容
临床试验/NCT01865786
NCT01865786已完成不适用

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication Nested in the Antiretroviral Pregnancy Registry

Gilead Sciences1 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2013年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
99
试验地点
1
主要终点
Presence or absence of congenital malformations among infants born to HIV-1 uninfected women on FTC/TDF for PrEP

研究概览

简要总结

This is a prospective, observational study to describe pregnancy outcomes among HIV-1 uninfected pregnant women who are taking emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication nested in the Antiretroviral Pregnancy Registry (APR).

Information on subjects is provided to the APR prospectively (prior to the outcome of the pregnancy being known) through their healthcare provider, with follow-up obtained from the healthcare provider following determination of the pregnancy outcome.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Pregnant women
  • Part of the prospective arm of the APR Target Group Inclusion Criteria
  • HIV-1 Negative
  • Choosing to remain on FTC/TDF for PrEP during pregnancy or,
  • Choosing to discontinue FTC/TDF for PrEP during pregnancy Comparison Group Inclusion Criteria
  • HIV-1 Positive
  • On antiretroviral therapy

排除标准

  • This is an observational nested study and will monitor all reported exposures without intervention/exclusion.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

结局指标

主要结局

Presence or absence of congenital malformations among infants born to HIV-1 uninfected women on FTC/TDF for PrEP

时间窗: Year 1

次要结局

  • Pregnancy outcomes in HIV-1 uninfected women who choose to continue or discontinue FTC/TDF for PrEP during their pregnancy as well as HIV-infected women treated with antiretrovirals(Years 1, 2, and 3)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验